Tore Saxne
#164,832
Most Influential Person Now
Tore Saxne's AcademicInfluence.com Rankings
Tore Saxnephilosophy Degrees
Philosophy
#9652
World Rank
#13241
Historical Rank
Logic
#6621
World Rank
#8154
Historical Rank
Download Badge
Philosophy
Why Is Tore Saxne Influential?
(Suggest an Edit or Addition)Tore Saxne's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. (1988) (582)
- Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. (2005) (581)
- IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. (1999) (487)
- Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas (2005) (455)
- Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. (2006) (427)
- The role of the cartilage matrix in osteoarthritis (2011) (424)
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists (2005) (421)
- Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. (2005) (418)
- Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists (2005) (411)
- Prognostic laboratory markers of joint damage in rheumatoid arthritis (2004) (396)
- Classification of osteoarthritis biomarkers: a proposed approach. (2006) (368)
- Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. (1992) (364)
- Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. (2014) (339)
- Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists (2007) (339)
- Radiographic osteoarthritis of the knee classified by the Ahlbäck and Kellgren & Lawrence systems for the tibiofemoral joint in people aged 35–54 years with chronic knee pain (1997) (323)
- Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. (2006) (308)
- Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden (2002) (271)
- Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register (2008) (268)
- Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. (1995) (262)
- Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. (2008) (262)
- Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? (2009) (259)
- Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. (1994) (243)
- Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. (1996) (242)
- Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. (1995) (221)
- Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. (2007) (211)
- Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. (1998) (209)
- Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis (2003) (208)
- Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis (1999) (194)
- Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. (2006) (191)
- Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats (1998) (186)
- Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage (2002) (182)
- Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis (2006) (177)
- Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden (2006) (174)
- Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register (2007) (169)
- Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation (2002) (169)
- Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. (2007) (169)
- Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. (2007) (158)
- The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. (2006) (138)
- Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. (2009) (138)
- Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. (2007) (135)
- Delays in assessment of patients with rheumatoid arthritis: variations across Europe (2011) (131)
- Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. (2011) (131)
- Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. (2003) (127)
- Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis (2013) (117)
- Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. (2010) (115)
- Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis (2003) (115)
- Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis (2006) (114)
- Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: A one year prospective study (1998) (108)
- Therapeutic effects on cartilage metabolism in arthritis as measured by release of proteoglycan structures into the synovial fluid. (1986) (106)
- Natural course of knee osteoarthritis in middle-aged subjects with knee pain: 12-year follow-up using clinical and radiographic criteria (2008) (105)
- Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. (1992) (103)
- Cartilage metabolism in the injured and uninjured knee of the same patient. (1994) (101)
- Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement (2008) (98)
- Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis. (1998) (97)
- Prediction of mortality in rheumatoid arthritis based on disease activity markers. (2005) (93)
- DIFFERENCE IN CARTILAGE PROTEOGLYCAN LEVEL IN SYNOVIAL FLUID IN EARLY RHEUMATOID ARTHRITIS AND REACTIVE ARTHRITIS (1985) (91)
- Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept (2003) (90)
- IL-1αβ Blockade Prevents Cartilage and Bone Destruction in Murine Type II Collagen-Induced Arthritis, Whereas TNF-α Blockade Only Ameliorates Joint Inflammation (1999) (88)
- Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. (1992) (87)
- Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept (2004) (87)
- Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register (2010) (87)
- Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria (2013) (86)
- Ten years with biologics: to whom do data on effectiveness and safety apply? (2011) (86)
- Association of Chondroadherin with Collagen Type II* (2001) (82)
- Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis (2012) (75)
- Postero-anterior radiogram of the knee in weight-bearing and semiflexion (1997) (74)
- Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis (2014) (74)
- Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. (2004) (74)
- Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. (1999) (73)
- Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training. (2010) (73)
- Synovial fluid acidosis correlates with radiological joint destruction in rheumatoid arthritis knee joints. (1989) (71)
- Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis (2006) (70)
- COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker (2007) (69)
- Inflammation is a feature of the disease process in early knee joint osteoarthritis. (2003) (69)
- The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review (2007) (68)
- Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. (2001) (67)
- Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paper (2007) (66)
- Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease. Relation to systemic treatment. (1987) (65)
- Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis. (1993) (64)
- Increased plasma levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to disease activity and nephritis (2011) (64)
- Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register (2010) (64)
- Predictors of infusion reactions during infliximab treatment in patients with arthritis (2006) (64)
- The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis (2016) (63)
- Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. (1997) (63)
- Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats (1998) (62)
- Up-regulation of cartilage oligomeric matrix protein at the onset of articular cartilage degeneration in a transgenic mouse model of osteoarthritis. (2000) (62)
- Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. (1995) (60)
- Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome (2012) (59)
- Involvement of nonarticular cartilage, as demonstrated by release of a cartilage-specific protein, in rheumatoid arthritis. (1989) (58)
- Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study (2012) (55)
- Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. (1993) (55)
- Cartilage markers in synovial fluid in symptomatic knee osteoarthritis (1997) (55)
- Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. (1999) (53)
- Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. (2007) (51)
- Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis (2012) (49)
- Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales (2005) (49)
- Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis. (1997) (48)
- Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis (2013) (48)
- National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients (2011) (47)
- Serum concentrations of cartilage oligomeric matrix protein, fibrinogen and hyaluronan distinguish inflammation and cartilage destruction in experimental arthritis in rats. (2002) (45)
- Interactions of the complement system with molecules of extracellular matrix: relevance for joint diseases. (2012) (44)
- Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden (2009) (44)
- Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden (2019) (44)
- Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. (2012) (44)
- Cytidine deaminase activity in synovial fluid of patients with rheumatoid arthritis: relation to lactoferrin, acidosis, and cartilage proteoglycan release. (1990) (43)
- Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs (2013) (43)
- Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis (2005) (43)
- Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study (2010) (43)
- PRELP Protein Inhibits the Formation of the Complement Membrane Attack Complex* (2012) (43)
- Relationships amongst osteoarthritis biomarkers, dynamic knee joint load, and exercise: results from a randomized controlled pilot study (2013) (42)
- Joint-space width in the axial view of the patello-femoral joint (1998) (42)
- Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction (1997) (42)
- Response criteria for rheumatoid arthritis in clinical practice: how useful are they? (2005) (42)
- Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. (2000) (41)
- Factors related to the progression of joint destruction in rheumatoid arthritis. (1984) (41)
- Increased concentrations of bone sialoprotein in joint fluid after knee injury. (1996) (40)
- Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis (2010) (40)
- Heavy Chains of Inter Alpha Inhibitor (IαI) Inhibit the Human Complement System at Early Stages of the Cascade* (2012) (40)
- An extra cysteine in one of the non-calcium-binding epidermal growth factor-like motifs of the FBN1 polypeptide is connected to a novel variant of Marfan syndrome. (1994) (39)
- Molecular markers of processes in cartilage in joint disease. (1991) (39)
- Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents (2009) (39)
- Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. (2017) (38)
- Fibronectin fragments cause release and degradation of collagen-binding molecules from equine explant cultures. (2004) (37)
- The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials (2011) (37)
- Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis (2016) (36)
- Immune response to collagen impregnated Dacron double velour grafts for aortic and aorto-femoral reconstructions. (1990) (36)
- Is Swollen to Tender Joint Count Ratio a New and Useful Clinical Marker for Biologic Drug Response in Rheumatoid Arthritis? Results From a Swedish Cohort (2014) (36)
- Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis (2011) (36)
- Interactions of histidine-rich glycoprotein with immunoglobulins and proteins of the complement system. (2009) (35)
- Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. (2000) (35)
- Measurement of synovial fluid volume using albumin dilution upon intraarticular saline injection. (1988) (35)
- Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease (2010) (35)
- Matrix proteins: potentials as body fluid markers of changes in the metabolism of cartilage and bone in arthritis. (1995) (34)
- Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine (2017) (34)
- Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis (1999) (34)
- Development of Functional Impairment and Disability in Rheumatoid Arthritis Patients Followed for 20 Years: Relation to Disease Activity, Joint Damage, and Comorbidity (2015) (33)
- Novel Cartilage Oligomeric Matrix Protein (COMP) Neoepitopes Identified in Synovial Fluids from Patients with Joint Diseases Using Affinity Chromatography and Mass Spectrometry* (2014) (33)
- Anti-inflammatory effects of contralateral administration of the kappa-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis. (2006) (32)
- Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. (2007) (31)
- Long-term mortality rate in rheumatoid arthritis patients with disease onset in the 1980s (2011) (30)
- Proteoglycan concentration in synovial fluid: predictor of future cartilage destruction in rheumatoid arthritis? (1987) (30)
- Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease. (2012) (29)
- Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment (2012) (29)
- Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. (1997) (28)
- Early changes in bone mineral density measured by digital X-ray radiogrammetry predict up to 20 years radiological outcome in rheumatoid arthritis (2011) (28)
- HLA DRB1* typing and cartilage oligomeric matrix protein (COMP) as predictors of joint destruction in recent-onset rheumatoid arthritis. (1997) (27)
- Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies (2017) (27)
- Release of cartilage and bone macromolecules into synovial fluid: differences between psoriatic arthritis and rheumatoid arthritis (2001) (27)
- Serum concentrations of two cartilage matrix proteins reflecting different aspects of cartilage turnover in relapsing polychondritis. (1995) (27)
- Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective (2016) (26)
- Recurrent fever caused by Candidatus Neoehrlichia mikurensis in a rheumatoid arthritis patient treated with rituximab. (2015) (24)
- A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis. (2013) (24)
- Serum concentrations of hyaluronan and proteoglycan in joint disease. Lack of association. (1991) (23)
- A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis (2014) (23)
- Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis – a prospective cohort study (2014) (22)
- Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts (2012) (22)
- Associations between APOE Genotypes and Disease Susceptibility, Joint Damage and Lipid Levels in Patients with Rheumatoid Arthritis (2013) (21)
- Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] (2004) (21)
- Quantification of cartilage oligomeric matrix protein (COMP) and a COMP neoepitope in synovial fluid of patients with different joint disorders by novel automated assays. (2017) (21)
- Association of genetic variants in the IL4 and IL4R genes with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts. (2013) (21)
- Cartilage proteoglycans in degenerative joint disease. (1987) (20)
- Bone mineral density in the hand as a predictor for mortality in patients with rheumatoid arthritis. (2009) (20)
- Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden (2016) (19)
- Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. (2017) (19)
- Human arthritic synovial fluid influences proteoglycan biosynthesis and degradation in organ culture of bovine nasal cartilage. (1988) (17)
- Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden (2010) (17)
- Biomarkers for cartilage and bone in rheumatoid arthritis (2006) (17)
- Matrix Glycoproteins and Proteoglycans in Cartilage (2005) (16)
- Macromolecular markers in joint disease. (1991) (16)
- Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register. (2008) (16)
- The heritable determinants of cartilage oligomeric matrix protein. (2006) (16)
- Radiographic assessment in relation to clinical and biochemical variables in rheumatoid arthritis. (1988) (15)
- Plasma levels of beta 2-microglobulin in rheumatoid arthritis. (1980) (15)
- Pentraxin 3 in serum and synovial fluid of patients with rheumatoid arthritis with and without autoantibodies (2017) (15)
- Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren’s syndrome and rheumatoid arthritis (2014) (15)
- Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis (2013) (15)
- The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients (2015) (14)
- Connective tissue macromolecules as markers for tissue processes in joint disease. (1991) (14)
- Increased serum cartilage oligomeric matrix protein levels and decreased patellar bone mineral density in patients with chondromalacia patellae (2002) (14)
- Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis (2016) (13)
- Molecular markers for assessment of cartilage damage in rheumatoid arthritis (2000) (13)
- Synovial fluid concentrations of interleukin-1 beta and proteoglycans are inversely related. (1988) (13)
- Serum COMP-C 3 b complexes in rheumatic diseases and relation to anti-TNF-alpha treatment (2012) (12)
- Cartilage derived proteoglycans in body fluids of children. Inverse correlation with age. (1989) (12)
- The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis (2004) (12)
- Cartilage oligomeric matrix protein: a new promising biomarker of liver fibrosis in chronic hepatitis C (2015) (12)
- Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment (2018) (11)
- Apolipoprotein E Triggers Complement Activation in Joint Synovial Fluid of Rheumatoid Arthritis Patients by Binding C1q (2020) (11)
- Non-collagenous Proteins; Glycoproteins and related proteins (2006) (10)
- Genetic variants in IL-15 associate with progression of joint destruction in rheumatoid arthritis, a multi cohort study (2012) (10)
- CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis (2004) (10)
- Sustained Remission in Tumor Necrosis Factor Inhibitor–treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study (2015) (9)
- Differences in Longitudinal Disease and Treatment Characteristics of Patients with Rheumatoid Arthritis Replying and Not Replying to a Postal Questionnaire. Experience from a Biologics Register in Southern Sweden (2009) (9)
- Cartilage macromolecules in knee joint synovial fluid. Markers of the disease course in patients with acute oligoarthritis (1997) (9)
- Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis (2018) (9)
- Noncollagenous Proteins: Glycoproteins and Related Proteins (2006) (9)
- Cartilage matrix macromolecules in lavage fluid of temporomandibular joints before and 6 months after diskectomy. (1997) (9)
- Arg519-Cys-associated haplotype in ice-landic family suggests early origin of this mutation (1996) (9)
- Cytidine deaminase and lactoferrin in inflammatory synovial fluids. Indicators of local polymorphonuclear cell function? (1992) (9)
- An examination of some molecular markers in blood and urine for discriminating patients with osteoarthritis from healthy individuals (1995) (8)
- The impact of IL-1Ra and MBL gene polymorphisms on joint damage after 5 and 10 years in patients with early rheumatoid arthritis. (2007) (8)
- No increase of severe infections in RA patients treated with TNF-blockers (2005) (8)
- A7.10 Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts (2012) (8)
- Recent developments and future research in the bone and joint decade 2000-2010. (2003) (8)
- Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis (2018) (8)
- Human monocyte elastolytic activity, the propeptides of types I and III procollagen, proteoglycans, and interleukin-6 in synovial fluid from patients with arthritis. (1991) (7)
- Differential release of molecular markers in joint disease. (1995) (6)
- Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al. (2004) (6)
- Changes in serum levels of cartilage and bone markers in early osteoarthritis of the knee (1995) (6)
- The Articular Cartilage (2008) (6)
- Secular trends of sustained remission in rheumatoid arthritis, a nationwide study in Sweden. (2019) (5)
- Risk of cardiovascular morbidity and mortality following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA (2005) (4)
- Immunologic response to collagen-impregnated vascular grafts. (1992) (4)
- Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study (2021) (4)
- 24th Scandinavian Congress of Rheumatology (1992) (4)
- Activation of Complement by Pigment Epithelium–Derived Factor in Rheumatoid Arthritis (2017) (4)
- Cyclosporin A in rheumatoid arthritis (2003) (3)
- [Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication]. (2007) (3)
- [The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis. A meta-analytic literature review--secondary publication]. (2009) (3)
- Preleukemic syndrome simulating SLE. A case report. (1982) (3)
- Safety and efficacy of adalimumab in arthritis patients previously treated with another biologic agent (2004) (3)
- Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. (2018) (3)
- Risk of tuberculosis in rheumatoid arthritis and following anti-TNF treatment. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA (2005) (3)
- Molecular markers for joint and skeletal diseases. An Eric K. Fernström symposium. Proceedings. (1995) (3)
- TNF-antagonist treatment and risk of hospitalisation for cardiovascular disease. Results from the National Swedish Monitoring-Program for Biologies in Ra (ARTIS). (2006) (3)
- COMP-C3b Complexes in Rheumatoid Arthritis with Severe Extraarticular Manifestations (2013) (2)
- Risk for lymphomas following TNF-blockade. Comparisons with a nationwide co-morbidity database (2004) (2)
- National EQ-5 D tariffs and quality-adjusted life-year estimation : comparison of UK , US and Danish utilities in south Swedish rheumatoid arthritis patients (2)
- Diagnosis of osteoarthritis in relation to molecular processes in cartilage: comment on the article by Clark et al. (2000) (2)
- SAT0047 Impact of Anti-Rheumatic Treatment on Immunogenicity of Pandemic H1N1 Influenza Vaccine in Patients with Arthritis (2013) (2)
- 313 THE NATURAL COURSE OF KNEE OSTEOARTHRITIS IN MIDDLE-AGED INDIVIDUALS WITH KNEE PAIN —A 12 YEAR FOLLOW-UP USING CLINICAL AND RADIOGRAPHIC CRITERIA (2008) (2)
- Molecular markers for joint disease. (1989) (2)
- TNF-antagonist treatment and risk of hospitalisation for infection. Results from the National Swedish Monitoring-Program for Biologics in RA (ARTIS). (2006) (2)
- Markers of joint tissue turnover in osteoarthritis (2002) (2)
- Markers of Cartilage Destruction (1992) (2)
- [New drugs against rheumatoid arthritis. Improved treatment options place new demands on health care organization]. (2000) (2)
- P224 IDENTIFICATION OF EARLY KNEE OSTEOARTHRITIS: RESULTS FROM THE DEVELOPMENT OF A MODEL FOR THE DIAGNOSIS OF EARLY KNEE OSTEOARTHRITIS (MODEKO) STUDY (2006) (2)
- Preleukemic Syndrome Simulating SLE (2009) (2)
- [Serious lung disease in RA and TNF-blockade--is there a connection?]. (2006) (1)
- THU0001 Variation in granzyme-b is associated with progression of joint destruction in rheumatoid arthritis (2013) (1)
- 5 – Articular cartilage (2015) (1)
- Diet‐Induced Arthritis in Pigs: Comment on the Article by Scher et al (2016) (1)
- Novel COMP Neoepitopes Identified in Synovial Fluids from Patients with Joint Diseases using Affinity Chromatography and Mass Spectrometry. Åhrman, (2014) (1)
- [Determination of matrix components in the synovial fluid and blood--a novel approach to studying cartilage involvement in joint disease]. (1989) (1)
- Cartilage macromolecules and the development of new methods for the assessment of joint disease (1997) (1)
- Limited impact of fibromodulin deficiency on the development of experimental skin fibrosis (2016) (1)
- cohort with early rheumatoid arthritis Course of radiographic damage over 10 years in a (2005) (1)
- A national database for co-morbidity in RA to evaluate drug safety. Solid cancers in RA and following anti-TNF treatment (2004) (1)
- Comment on: Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor a blockade. Authors' reply (2004) (1)
- Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis. (2022) (1)
- Activation of complement by pigment epithelium-derived factor (PEDF) in rheumatoid arthritis (2017) (0)
- OP0089 Genetic studies on DICKKOPF-1, sclerostin and the severity of joint destruction in rheumatoid arthritis (2013) (0)
- Lymphomas in RA patients treated with TNF-blockers. Cases found in a post-marketing surveillance in Sweden (2004) (0)
- Swedish Arthritis Treatment Group Register psoriatic arthritis patients: Results from the South Efficacy and tolerability of anti-TNF therapy in (2007) (0)
- Risk of hospitalisation for infections following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA (2005) (0)
- The Swedish biologics register (ARTIS): observations of adverse events when using biologics in clinical practice (2008) (0)
- Plasma levels of32-microglobulin inrheumatoid arthritis (1980) (0)
- Biomarkers in the prediction of radiographic progression in early rheumatoid arthritis: comment on the article by Young-Min et al - Reply (2008) (0)
- Health utilities improvement during TNF blockade in chronic arthritis occurs early in the treatment course, results from an eight year observational study in southern Sweden (2008) (0)
- ReviewClassification of osteoarthritis biomarkers: a proposed approach 1 (0)
- Genetic control of arthritis in rats (2000) (0)
- Peer-reviewed publications (2016) (0)
- Authors' reply (1995) (0)
- Early rheumatoid arthritis patients with DR4 shared epitope alleles progress radiologically and have elevated levels of serum MMP-3, serum comp, urinary GLC-GAL-PYD and urinary collagen crosslinks (2005) (0)
- Markers of cartilage destruction. In Rheumatoid Arthritis. Recent Research Advances (1992) (0)
- Hormone replacement therapy , calcium and vitamin D 3 versus calcium and vitamin D 3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis : a randomized controlled trial [ ISRCTN 46523456 ] (2015) (0)
- COMP-C3b as a molecular marker for inflammatory joint diseases (2011) (0)
- Experience from a Biologics Register in Southern Sweden with Rheumatoid Arthritis Replying and Not Replying to a Postal Differences in Longitudinal Disease and Treatment Characteristics of Patients (2009) (0)
- Citrullinated proteins are present in synovial fluids from inflammatory arthritis but not osteoarthritis (2008) (0)
- FRI0162 Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis (RA) or sjogrens syndrome without dmard treatment compared to controls (2017) (0)
- S100A8/A9 in bleomycin-induced skin fibrosis (2011) (0)
- Hormone replacement therapy, calcium an d vitamin D 3 versus calcium an d vitamin D 3 alone decreases markers of cartilage an d bone metabolism in rheumatoi d arthritis: a ran domized controlle d trial [ISRCTN46523456]. (2004) (0)
- Biomarkers of complement activation in synovial fluid from patients with knee injuries and osteoarthritis (2016) (0)
- PRELP protein inhibits the formation of the complement membrane attack complex. (2012) (0)
- P108 TQOL-LITE: A SIMPLIFIED ASSESSMENT TOOL FOR TOTAL QUANTITATIVE OSTEOARTHRITIS (OA) LOAD (2006) (0)
- generalised osteoporosis rheumatoid arthritis is strongly associated with Radiographic joint destruction in postmenopausal (2005) (0)
- SAT0099 Contribution of disease activity, joint damage and comorbidity to impairment and disability in rheumatoid arthritis patients during 20 years (2013) (0)
- Biomarkers of cartilage degradation and synthesis relevant to knee osteoarthritis: relationships with dynamic knee joint load and changes following exercise (2012) (0)
- FRI0082 Development of impairment, disability, radiological damage, comorbidity and mortality over 20 years in rheumatoid arthritis patients (2013) (0)
- Automated assays for the quantification of total cartilage oligomeric matrix protein (COMP) and a COMP neoepitope (2016) (0)
- Reumatologisk forskning i Lund/Malmö (2013) (0)
- Activation of complement by pigment epithelium derived protein in synovial fluid of rheumatoid arthritis patients (2016) (0)
- Association of biomarkers with osteoarthritis progression based on MRI: results from the Vancouver knee osteoarthritis progression (KOAP) study (2013) (0)
- THU0363 Efficacy and Tolerability of Anti-TNF Therapies in Patients with Non-Radiographic Axial Spondyloarthritis: An Observational Cohort Study from Southern Sweden (2013) (0)
- Polymorfisms In IL15 Associate with Progression of Joint Destruction In Rheumatoid Arthritis; A Multi Cohort Study (2011) (0)
- Reduced Risk of Serious Pneumococcal Infection Up to 10 Years After 7-Valent Pneumococcal Conjugate Vaccine in Arthritis Patients (2021) (0)
- [To describe arthrosis as a "degenerative joint disease" is obsolete]. (2002) (0)
- Associations of clinical and biomarker variables with cartilage damage in painful pre-radiographic knee osteoarthritis. results from a population-based study (2013) (0)
- Increased serum levels of cartilage oligomeric matrix protein precede the clinical onset of rheumatoid arthritis despite lower levels among smokers (2008) (0)
- The Journal of Rheumatology ManifestationsCOMP-C3b Complexes in Rheumatoid Arthritis with Severe Extraarticular (2013) (0)
- Genetic variants in OPG are associated with progression of joint destruction in Rheumatoid Arthritis (2014) (0)
- FRI0213 The Association between Antibody Levels before and after 7-Valent Pneumococcal Conjugate Vaccine Immunization and Subsequent Pneumococcal Infection in Arthritis Patients (2014) (0)
- Post-translational modifications of ApoE: Modulation of complement in synovial fluid of rheumatoid arthritis patients? (2018) (0)
- The osteoarthritis biomarker comp: Serum levels are genetically determined (2005) (0)
- High serum levels of cartilage oligomeric matrix protein during pristane induced arthritis reflects a severe and chronic disease (1997) (0)
- Inflammation and joint disease: Molecules/fragments that are released upon cartilage breakdown can activate complement and provide a new diagnostics for pathological complement activation (2010) (0)
- The dominant role of serum MMP-3 compared to serum MMP-1 and MMP-13 in the generation of breakdown products from joint tissues in patients with early rheumatoid arthritis (2005) (0)
- [Rheumatologic research with animal experiments is important for our patients]. (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Tore Saxne?
Tore Saxne is affiliated with the following schools:
